Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level
Context Various molecular mechanisms play a role in the development of resistance to
androgen deprivation therapy in castration-resistant prostate cancer (CRPC). Objective To …
androgen deprivation therapy in castration-resistant prostate cancer (CRPC). Objective To …
[HTML][HTML] The many faces of neuroendocrine differentiation in prostate cancer progression
In normal prostate, neuroendocrine (NE) cells are rare and interspersed among the
epithelium. These cells are believed to provide trophic signals to epithelial cell populations …
epithelium. These cells are believed to provide trophic signals to epithelial cell populations …
Clusterin, other extracellular chaperones, and eye disease
Proteostasis refers to all the processes that maintain the correct expression level, location,
folding and turnover of proteins, essential to organismal survival. Both inside cells and in …
folding and turnover of proteins, essential to organismal survival. Both inside cells and in …
[HTML][HTML] Exercise medicine for advanced prostate cancer
Exercise oncology is rapidly evolving, with impressive possibilities that may directly improve
patient outcomes in advanced prostate cancer. Research must focus on translating …
patient outcomes in advanced prostate cancer. Research must focus on translating …
Serum tri‐ and tetra‐antennary N‐glycan is a potential predictive biomarker for castration‐resistant prostate cancer
Y Ishibashi, Y Tobisawa, S Hatakeyama… - The …, 2014 - Wiley Online Library
BACKGROUND The US FDA has approved several novel systemic agents including
abiraterone acetate and taxoid cabazitaxel for metastatic castration‐resistant prostate …
abiraterone acetate and taxoid cabazitaxel for metastatic castration‐resistant prostate …
RNA‐binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression
J Zhao, Y Zhang, X Liu, F Zhu, F Xie, C Jiang… - Cancer …, 2020 - Wiley Online Library
The androgen receptor (AR) pathway is critical for prostate cancer carcinogenesis and
development; however, after 18‐24 months of AR blocking therapy, patients invariably …
development; however, after 18‐24 months of AR blocking therapy, patients invariably …
[HTML][HTML] Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment
H Uemura, N Matsubara, G Kimura, A Yamaguchi… - BMC urology, 2016 - Springer
Background Up to a fifth of patients diagnosed with prostate cancer (PC) will develop
castration-resistant prostate cancer (CRPC), which has been associated with a poor …
castration-resistant prostate cancer (CRPC), which has been associated with a poor …
Clusterin in the eye: an old dog with new tricks at the ocular surface
The multifunctional protein clusterin (CLU) was first described in 1983 as a secreted
glycoprotein present in ram rete testis fluid that enhanced aggregation ('clustering') of a …
glycoprotein present in ram rete testis fluid that enhanced aggregation ('clustering') of a …
Neutrophil-to-lymphocyte ratio as a predictive marker of response to abiraterone acetate: a retrospective analysis of the COU302 study
T Loubersac, M Nguile-Makao, F Pouliot… - European Urology …, 2020 - Elsevier
Background The neutrophil-lymphocyte ratio (NLR) is an inexpensive and accessible
prognostic marker for many cancers, including metastatic castration-resistant prostate …
prognostic marker for many cancers, including metastatic castration-resistant prostate …
[HTML][HTML] Clusterin seals the ocular surface barrier in mouse dry eye
Dry eye is a common disorder caused by inadequate hydration of the ocular surface that
results in disruption of barrier function. The homeostatic protein clusterin (CLU) is prominent …
results in disruption of barrier function. The homeostatic protein clusterin (CLU) is prominent …